Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Earnings Data
Report Date
Mar 23, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.33Last Year’s EPS
0.5Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook for Abeona Therapeutics, with strong advancements in the commercial launch of ZivaSkin, expansion of treatment centers, and favorable market access. However, there were notable challenges, including delays in patient treatment and increased SG&A expenses. The company's financial position remains strong, and its pipeline shows promising advancements.Company Guidance
ZivaSkin Commercial Launch Progress
Patient demand for ZivaSkin is increasing, with product order forms received for 12 patients. The number of identified eligible patients at qualified treatment centers has more than doubled to approximately 30.
Expansion of Qualified Treatment Centers
Children's Hospital Colorado has been added as a new qualified treatment center, bringing the total to three. Discussions are ongoing with other centers to expand the network further.
Strong Market Access for ZivaSkin
Positive coverage decisions from major commercial and government payers have been secured, covering over 80% of commercially insured lives. ZivaSkin has baseline coverage across all state Medicaid programs, and a permanent product J code will be effective from January 2026.
Financial Stability
The company has a robust cash position of $207.5 million, expected to fund operations for over two years without anticipated revenue from ZivaSkin. The net loss decreased significantly to $5.2 million from $30.3 million in the previous year.
Pipeline Advancements
The company's gene therapy program for X-linked retinoschisis is part of the FDA Rare Disease Endpoint Advancement pilot program. Additionally, Dr. James A. Gao has been appointed as Senior Vice President, Head of Clinical Development and Medical Affairs.
ABEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $4.17 | $4.94 | +18.47% |
Aug 14, 2025 | $6.56 | $7.23 | +10.21% |
May 15, 2025 | $5.39 | $5.79 | +7.42% |
Mar 20, 2025 | $5.20 | $5.14 | -1.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Abeona Therapeutics (ABEO) report earnings?
Abeona Therapeutics (ABEO) is schdueled to report earning on Mar 23, 2026, TBA (Confirmed).
What is Abeona Therapeutics (ABEO) earnings time?
Abeona Therapeutics (ABEO) earnings time is at Mar 23, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABEO EPS forecast?
ABEO EPS forecast for the fiscal quarter 2025 (Q4) is -0.33.